Neogenomics (NYSE:NEO) updated its second quarter earnings guidance on Wednesday. The company provided EPS guidance of $0.00-0.01 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.00, AnalystRatings.NET reports. The company issued revenue guidance of $18.8-19.3 million, compared to the consensus revenue estimate of $17.27 million.
On a related note, analysts at Stephens initiated coverage on shares of Neogenomics in a research note on Friday, February 14th. They set an overweight rating and a $6.00 price target on the stock. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The company currently has an average rating of Buy and a consensus price target of $6.50.
Neogenomics (NYSE:NEO) opened at 3.48 on Wednesday. Neogenomics has a 52 week low of $2.05 and a 52 week high of $4.69. The stock’s 50-day moving average is $3.43 and its 200-day moving average is $3.59. The company has a market cap of $170.9 million and a price-to-earnings ratio of 86.25.
Neogenomics (NYSE:NEO) last released its earnings data on Wednesday, February 19th. The company reported $0.04 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.02 by $0.02. The company had revenue of $18.30 million for the quarter, compared to the consensus estimate of $17.80 million. On average, analysts predict that Neogenomics will post $0.01 earnings per share for the current fiscal year.
NeoGenomics, Inc (NYSE:NEO) operates a network of cancer-focused testing laboratories.
Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.